On November 28, a delegation led by Professor Chen Chun, Vice President of the Seventh Affiliated Hospital of Sun Yat-sen University, Discipline Leader of Pediatric Hematology and Oncology, and Director of the Pediatrics Teaching and Research Office at Sun Yat-sen University School of Medicine; Director Xue Hongman of the Pediatrics Department; and Professor Huang Junbin visited Shenzhen Cell Valley for exchange and discussion. Our Chairman, Professor Shi Yuanyuan, Deputy General Manager Tang Xiaomeng, Commercial Director Tang Hui, Head of R&D Zhao Lijun, and Head of Marketing Sun Rui extended a warm welcome to the delegation.

Accompanied by Head of Marketing Sun Rui, the team toured the smart exhibition hall, the digital monitoring platform, and the production and quality control workshops. They gained an initial understanding of the company's strategic development layout, corporate history, core team, core technology patents, the development history and current status of cell therapy, the role and advantages of retroviral vectors in cell therapy, as well as the Shenzhen and Zhongshan bases for production, R&D, quality management, and industrial talent training. They also developed a deeper appreciation of the comprehensive, one-stop service process provided by Shenzhen Cell Valley, spanning from fundamental scientific research to clinical translation.

During the symposium, Professor Shi Yuanyuan extended a warm welcome to the clinical experts from the Seventh Affiliated Hospital of Sun Yat-sen University. Subsequently, the two sides engaged in discussions on cooperation plans for co-building cell therapy platforms, conducting IIT clinical research explorations in pediatric hematology and oncology, and translating subsequent innovative directions into practical projects.

Head of Marketing Sun Rui provided a detailed introduction to Shenzhen Cell Valley's core advantages and the use of its domestically leading GMP-grade industrial-scale production processes for retroviral vectors. Professor Shi Yuanyuan noted that cell therapy has achieved remarkable success in improving patient survival rates and reducing the cancer burden. Leveraging its advantages in industrial-scale production processes, the company provides high-quality and safe cell preparation services to multiple top-tier tertiary hospitals, jointly advancing clinical research and application development in cell therapy. Dozens of patients with hematologic malignancies who had failed prior treatments and experienced relapse or drug resistance have achieved significant remission after receiving CAR-T cells prepared by the Cell Valley team. Additionally, the NK and CAR-NK cell therapy products recently launched by Cell Valley have been widely applied in clinical research for hematologic malignancies. Shenzhen Cell Valley remains committed to its mission and values of "Cells benefit all, genes create the future," dedicated to addressing key constraints in cell therapy drugs/clinical treatment—including technology, cost, production capacity, and talent—and to opening more therapeutic pathways for patients.

President Chen Chun noted that cell therapy is emerging as a new focal point in the development of the healthcare industry. The future model of clinical cell therapy will be full-cycle and comprehensive, and its widespread adoption and promotion will rely on the sustained technological development by research teams, as well as the translational application by high-level clinical diagnostic and therapeutic teams.

Both parties expressed their commitment to fully leveraging their respective technological resources, core teams, and platform advantages, and to jointly advancing the scientific research and clinical application of cell therapy in pediatric hematology and oncology.